Q3 EPS Forecast for Rhythm Pharmaceuticals Raised by Analyst

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in a research note issued to investors on Thursday, August 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.72) for the quarter, up from their prior estimate of ($0.73). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.86) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.41) EPS.

A number of other analysts have also issued reports on RYTM. Wall Street Zen raised Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, July 26th. Morgan Stanley lifted their price objective on Rhythm Pharmaceuticals from $100.00 to $109.00 and gave the company an “overweight” rating in a research note on Tuesday, August 5th. Bank of America lifted their price objective on Rhythm Pharmaceuticals from $73.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, July 10th. Guggenheim lifted their price objective on Rhythm Pharmaceuticals from $119.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Finally, Oppenheimer lifted their price objective on Rhythm Pharmaceuticals from $76.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, July 10th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $101.57.

Rhythm Pharmaceuticals Trading Up 2.5%

Shares of NASDAQ:RYTM opened at $94.31 on Monday. The stock’s 50-day moving average price is $75.98 and its two-hundred day moving average price is $64.02. Rhythm Pharmaceuticals has a 12-month low of $43.57 and a 12-month high of $94.80. The firm has a market cap of $6.26 billion, a price-to-earnings ratio of -31.33 and a beta of 2.38.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). The company had revenue of $48.50 million for the quarter, compared to analysts’ expectations of $43.72 million. Rhythm Pharmaceuticals had a negative return on equity of 1,831.43% and a negative net margin of 117.13%. The company’s revenue for the quarter was up 66.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.55) EPS.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in Rhythm Pharmaceuticals by 2.6% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 95,517 shares of the company’s stock worth $6,036,000 after buying an additional 2,412 shares during the last quarter. Creative Planning grew its stake in Rhythm Pharmaceuticals by 39.6% during the 2nd quarter. Creative Planning now owns 17,222 shares of the company’s stock worth $1,088,000 after buying an additional 4,889 shares during the last quarter. Candriam S.C.A. grew its stake in Rhythm Pharmaceuticals by 7.2% during the 2nd quarter. Candriam S.C.A. now owns 312,452 shares of the company’s stock worth $19,745,000 after buying an additional 20,983 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in Rhythm Pharmaceuticals by 6.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 12,359 shares of the company’s stock worth $781,000 after buying an additional 704 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Rhythm Pharmaceuticals by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,311,253 shares of the company’s stock worth $82,868,000 after buying an additional 24,085 shares during the last quarter.

Insiders Place Their Bets

In other news, insider Alastair Garfield sold 1,319 shares of the business’s stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $64.81, for a total value of $85,484.39. Following the completion of the sale, the insider directly owned 3,126 shares in the company, valued at approximately $202,596.06. The trade was a 29.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Pamela J. Cramer sold 1,520 shares of the business’s stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $85.93, for a total value of $130,613.60. Following the completion of the sale, the insider owned 20,814 shares of the company’s stock, valued at $1,788,547.02. This trade represents a 6.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,417 shares of company stock worth $6,352,511. Corporate insiders own 6.10% of the company’s stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.